Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products.
Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair.
It has collaborations with MSD (Merck & Co., Inc.), Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, and University of Adelaide in Ulcerative Colitis.
News Highlights
- Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma 12 April 2023
- Microbiotica announces transition of leadership 29 November 2022
- Microbiotica to present at key industry conferences in Q3 2022 20 June 2022
Careers
Contact us at recruitment@microbiotica.com.